MX2024001777A - Derivado de sulfonamida, metodo de preparacion y uso medico del mismo. - Google Patents
Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.Info
- Publication number
- MX2024001777A MX2024001777A MX2024001777A MX2024001777A MX2024001777A MX 2024001777 A MX2024001777 A MX 2024001777A MX 2024001777 A MX2024001777 A MX 2024001777A MX 2024001777 A MX2024001777 A MX 2024001777A MX 2024001777 A MX2024001777 A MX 2024001777A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- medical use
- sulfonamide derivative
- sulfonamide
- derivative
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 102000007077 Lysine Acetyltransferases Human genes 0.000 abstract 1
- 108010033293 Lysine Acetyltransferases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110913249 | 2021-08-10 | ||
| CN202111142090 | 2021-09-28 | ||
| CN202111500231 | 2021-12-09 | ||
| PCT/CN2022/111395 WO2023016484A1 (zh) | 2021-08-10 | 2022-08-10 | 磺酰胺衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001777A true MX2024001777A (es) | 2024-02-29 |
Family
ID=85200573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001777A MX2024001777A (es) | 2021-08-10 | 2022-08-10 | Derivado de sulfonamida, metodo de preparacion y uso medico del mismo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250145637A1 (https=) |
| EP (1) | EP4385989A4 (https=) |
| JP (1) | JP2024529068A (https=) |
| KR (1) | KR20240046530A (https=) |
| CN (1) | CN117597341A (https=) |
| AU (1) | AU2022325367A1 (https=) |
| CA (1) | CA3228411A1 (https=) |
| MX (1) | MX2024001777A (https=) |
| TW (1) | TW202321263A (https=) |
| WO (1) | WO2023016484A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118556053A (zh) | 2021-11-16 | 2024-08-27 | 英矽智能科技知识产权有限公司 | 赖氨酸乙酰基转移酶6a(kat6a)抑制剂及其用途 |
| WO2023114710A1 (en) * | 2021-12-13 | 2023-06-22 | Aurigene Oncology Limited | Fused benzoisoxazolyl compounds as kat6a inhibitors |
| CN116621859A (zh) * | 2022-02-18 | 2023-08-22 | 山东轩竹医药科技有限公司 | 三并环类kat6抑制剂 |
| KR20250006833A (ko) | 2022-03-28 | 2025-01-13 | 아이소스테릭스, 인코포레이티드 | 라이신 아세틸 전이효소의 myst 계열의 억제제 |
| KR20250143814A (ko) * | 2023-02-10 | 2025-10-02 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 설폰아미드 유도체 결정 형태 및 이의 제조 방법 |
| WO2024189598A2 (en) | 2023-03-16 | 2024-09-19 | Olema Pharmaceuticals, Inc. | Acylsulfonamide kat6a inhibitors |
| CN120981721A (zh) * | 2023-03-30 | 2025-11-18 | 辉瑞大药厂 | Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法 |
| AU2024290895A1 (en) | 2023-07-04 | 2026-01-29 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Kat6 inhibitor |
| WO2025098417A1 (zh) * | 2023-11-08 | 2025-05-15 | 再和医药科技（苏州）有限公司 | 磺酰胺类化合物及其应用 |
| WO2025101942A1 (en) * | 2023-11-10 | 2025-05-15 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
| AR134697A1 (es) * | 2023-12-18 | 2026-03-04 | Ideaya Biosciences Inc | Compuestos químicos y sus usos |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750542A (en) * | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| HU225047B1 (en) * | 1991-03-28 | 2006-05-29 | Eisai Co Ltd | Heterocyclic-piperidin-derivatives, pharmaceutical compositions containing them and process for their production |
| WO2002074746A1 (en) * | 2001-03-16 | 2002-09-26 | Yamanouchi Pharmaceutical Co., Ltd. | Benzazepine derivatives |
| KR100965021B1 (ko) * | 2002-02-22 | 2010-06-21 | 바이엘 파마슈티칼스 코포레이션 | 과다증식성 질환 치료에 유용한 벤조푸란 및 벤조티오펜유도체 |
| AU2006281803B9 (en) * | 2005-08-18 | 2013-05-30 | Genmab A/S | Therapy with CD4 binding peptides and radiation |
| CN105492430B (zh) * | 2013-03-15 | 2017-10-10 | 基因泰克公司 | 取代的苯并噁唑及其使用方法 |
| WO2015102929A1 (en) * | 2013-12-30 | 2015-07-09 | Novartis Ag | Tricyclic sulfonamide derivatives |
| JP6568926B2 (ja) * | 2014-03-20 | 2019-08-28 | カペラ セラピューティクス，インコーポレーテッド | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 |
| GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| WO2017218960A1 (en) | 2016-06-17 | 2017-12-21 | Fronthera U.S. Pharmaceuticals Llc | Hemoglobin modifier compounds and uses thereof |
| GB201713962D0 (en) | 2017-08-31 | 2017-10-18 | Ctxt Pty Ltd | Compounds |
| MX2020007131A (es) | 2017-11-29 | 2021-01-08 | Epizyme Inc | Inhibidores de histona acetiltransferasa de la familia myst. |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| KR20210057767A (ko) * | 2018-09-07 | 2021-05-21 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Crbn단백질에 작용하는 삼환식 화합물 |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| CA3137472A1 (en) | 2019-04-25 | 2020-10-29 | Bayer Aktiengesellschaft | Acyl sulfonamides for treating cancer |
| DK4299135T3 (da) * | 2019-06-18 | 2025-09-08 | Pfizer | Benzisoxazol-sulfonamid-derivater |
| US12545669B2 (en) | 2019-06-19 | 2026-02-10 | Pfizer Inc. | Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives |
-
2022
- 2022-08-10 US US18/682,647 patent/US20250145637A1/en active Pending
- 2022-08-10 WO PCT/CN2022/111395 patent/WO2023016484A1/zh not_active Ceased
- 2022-08-10 JP JP2024507166A patent/JP2024529068A/ja active Pending
- 2022-08-10 AU AU2022325367A patent/AU2022325367A1/en active Pending
- 2022-08-10 TW TW111130097A patent/TW202321263A/zh unknown
- 2022-08-10 KR KR1020247007144A patent/KR20240046530A/ko active Pending
- 2022-08-10 EP EP22855464.8A patent/EP4385989A4/en active Pending
- 2022-08-10 MX MX2024001777A patent/MX2024001777A/es unknown
- 2022-08-10 CN CN202280046780.6A patent/CN117597341A/zh active Pending
- 2022-08-10 CA CA3228411A patent/CA3228411A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024529068A (ja) | 2024-08-01 |
| AU2022325367A1 (en) | 2024-02-08 |
| WO2023016484A1 (zh) | 2023-02-16 |
| CA3228411A1 (en) | 2023-02-16 |
| EP4385989A4 (en) | 2024-12-18 |
| CN117597341A (zh) | 2024-02-23 |
| KR20240046530A (ko) | 2024-04-09 |
| EP4385989A1 (en) | 2024-06-19 |
| US20250145637A1 (en) | 2025-05-08 |
| TW202321263A (zh) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001777A (es) | Derivado de sulfonamida, metodo de preparacion y uso medico del mismo. | |
| MX2024004846A (es) | Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| JOP20240124A1 (ar) | مركبات 2-أمينو-3-سيانو ثيوفين حلقية ومشتقاتها لعلاج السرطان | |
| CO2022017049A2 (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
| JOP20220271A1 (ar) | مركبات دايازينو بيريميدين كمثبطات لـ her2 | |
| NZ777871A (en) | Small molecule modulators of il-17 | |
| MX2023000314A (es) | Formulaciones farmaceuticas transdermicas de cannabinoides. | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| CL2023000921A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead | |
| PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| BR112022020933A2 (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| BR112023022647A2 (pt) | Derivado de 7-nitro-8-hidroxiquinolina, método de preparação do mesmo e uso médico do mesmo | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| GEAP202516720A (en) | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof | |
| BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| JOP20220319B1 (ar) | أزيلاستين كعلاج مضاد للفيروسات | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| BR112019008698A2 (pt) | método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica |